TG Therapeutics, Inc.
TGTX
Hisse Senetlerindeki Sıralama
#2354
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Hisse Fiyatı
$54.70
Son senkronizasyon: 2026-10-20
Piyasa Değeri
$8.37B
Değişim (1 gün)
2.63%
Değişim (1 yıl)
55.31%
Ülke
US
Ticaret TG Therapeutics, Inc. (TGTX)
Kategori
Healthcare
TG Therapeutics, Inc. (TGTX) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 141.77M
TG Therapeutics, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 141.77M'dir. December 2023 sonunda şirketin 141.96M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
TG Therapeutics, Inc. (TGTX) için 2000 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 141.77M | -2.44% |
| 2024 | 145.32M | 2.37% |
| 2023 | 141.96M | 4.83% |
| 2022 | 135.41M | 2.41% |
| 2021 | 132.22M | 14.64% |
| 2020 | 115.33M | 30.51% |
| 2019 | 88.37M | 17.10% |
| 2018 | 75.47M | 21.58% |
| 2017 | 62.07M | 26.57% |
| 2016 | 49.04M | 7.44% |
| 2015 | 45.65M | 33.98% |
| 2014 | 34.07M | 34.06% |
| 2013 | 25.41M | 93.80% |
| 2012 | 13.11M | 580.81% |
| 2011 | 1.93M | 4,742.37% |
| 2010 | 39.78K | 58.41% |
| 2009 | 25.11K | 0.00% |
| 2008 | 25.11K | 3.84% |
| 2007 | 24.18K | 13.15% |
| 2006 | 21.37K | 38.05% |
| 2005 | 15.48K | 61.66% |
| 2004 | 9.58K | 20.31% |
| 2003 | 7.96K | 78.92% |
| 2002 | 4.45K | 291.98% |
| 2001 | 1.14K | 160.92% |
| 2000 | 435.00 | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 79.09% |
US
|
|
| 396.00M | 179.33% |
US
|
|
| 478.91M | 237.81% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -56.14% |
NL
|
